title: A preliminary study on the interaction of fluvoxamine and adenosine receptor on isolated Guinea-pig atria.
abstract: Fluvoxamine (FLV), a selective serotonin reuptake inhibitor (SSRI) antidepressant, caused a dose-dependent decrease in rate and contractile force of the isolated guinea-pig atria. These effects significantly blocked by DPCPX, a specific A(1) receptor antagonist. Theophylline, an A(1)/A(2A) receptor antagonist, also prevented the inotropic and chronotropic effect of FLV. The atrium was dissected out and suspended in modified Krebs solution under physiologic conditions. Drug was added to the solution. The changes in rate and contractions were measured using a physiograph. The data indicate that DPCPX and theophylline prevent the inotropic and chronotropic effects of FLV on atria, but these effects were not prevented by atropine and DMPX, an A(2) receptor antagonist. Adenosine A(1) receptor blockade attenuates FLV effects in isolated guinea-pig atria.
authors.affiliation: Department of Pharmacology, School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Abbas
authors.initials: A
authors.lastname: Pousti
authors.forename: Tara
authors.initials: T
authors.lastname: Deemyad
authors.forename: Golrokh
authors.initials: G
authors.lastname: Malihi
authors.forename: Kaveh
authors.initials: K
authors.lastname: Brumand
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D016666:Fluvoxamine / Q000494:pharmacology*; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects*; D006325:Heart Atria / Q000187:drug effects / Q000378:metabolism; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010865:Pilot Projects; D018340:Receptors, Adrenergic, alpha-1 / Q000378:metabolism*; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013806:Theophylline / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D058669:Adrenergic alpha-2 Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D001285:Atropine; D016666:Fluvoxamine; D010726:Phosphodiesterase Inhibitors; D018340:Receptors, Adrenergic, alpha-1; D018341:Receptors, Adrenergic, alpha-2; D017367:Selective Serotonin Reuptake Inhibitors; D013806:Theophylline; D014970:Xanthines; C051360:1,3-dipropyl-8-cyclopentylxanthine